GT Biopharma Inc (GTBP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.67M
Last updated: Nov 17, 2026 at 11:02 AM ET
GT Biopharma Inc (GTBP) Stock Forecast
Analysts expect GT Biopharma (GTBP) to earn -$10.75 per share in the fiscal year ending Dec 31, 2026. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$8.00.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$10.75
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$8.00
- EPS consensus
- Next report
- Mar 1, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$10.75 | -$10.75 to -$10.75 | 1 |
| Dec 31, 2027 | -$8.00 | -$8.00 to -$8.00 | 1 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$2.55 | N/A | 3 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$8.50.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$10.75 | -$8.50 | -$8.50 | -$8.50 | -$8.50 | N/A |
| Fiscal year ending Dec 31, 2027 | -$8.00 | -$6.75 | -$6.75 | -$6.75 | -$6.75 | N/A |
Frequently Asked Questions About GTBP
What is the GTBP stock forecast?
Consensus analyst estimates put GT Biopharma's EPS at -$10.75 for the fiscal year ending Dec 31, 2026.
What EPS do analysts expect from GTBP next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$10.75, with estimates from -$10.75 to -$10.75 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$8.00, with estimates from -$8.00 to -$8.00 from 1 analyst.
How many analysts cover GTBP?
1 analyst estimates EPS for GT Biopharma for the fiscal year ending Dec 31, 2026.
GTBP pages: Overview, Earnings, Forecast, Financials, Competitors